Baird raised the firm’s price target on Alkermes (ALKS) to $41 from $38 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results as they look to Q3 for commercial growth ahead of key Phase 2 Orexin results.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes Hold Rating: Balancing Orexin Program Prospects and Competitive Risks
- Alkermes plc Reports Q1 2025 Financial Results
- Alkermes plc Earnings Call Highlights Growth and R&D Progress
- Alkermes Inc.: Strong Buy Rating Driven by Robust Financial Performance and Promising Pipeline Potential
- Alkermes reports Q1 EPS 13c, consensus 24c